IP Library › Granted Patent US 9,228,008
Granted Patent B2
US 9,228,008 · App. 12/941,583 · Granted Jan 5, 2016

Canine anti-CD20 antibodies

Inventor: Melissa J. Beall (Cape Elizabeth, ME)
Assignee: IDEXX Laboratories, Inc.
C07K14/70596A61K39/39541A61K39/39558C07K16/2887C07K16/3061C12N5/163G01N33/5052G01N33/564C07K2317/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,228,008
App. No.
12/941,583
Granted
Jan 5, 2016
Kind
B2
Abstract

The invention provides canine CD20 specific antibodies, methods of making the antibodies and methods of use of the antibodies.

Claims (22)

1. An isolated antibody or antigen-binding portion thereof that specifically binds canine CD20, wherein the antibody comprises:

(i) a VH CDR1 of SEQ ID NO:9, a VH CDR2 of SEQ ID NO:10, VH CDR3 of SEQ ID NO:11, a VL CDR1 of SEQ ID NO:21, a VL CDR2 of SEQ ID NO:22, and a VL CDR3 of SEQ ID NO:23;

(ii) a VH CDR1 of SEQ ID NO:12, a VH CDR2 of SEQ ID NO:13, VH CDR3 of SEQ ID NO:14, a VL CDR1 of SEQ ID NO:24, a VL CDR2 of SEQ ID NO:25, and a VL CDR3 of SEQ ID NO:26;

(iii) a VH CDR1 of SEQ ID NO:15, a VH CDR2 of SEQ ID NO:16, VH CDR3 of SEQ ID NO:17, a VL CDR1 of SEQ ID NO:27, a VL CDR2 of SEQ ID NO:28, and a VL CDR3 of SEQ ID NO:29; or

(iv) a VH CDR1 of SEQ ID NO:18, a VH CDR2 of SEQ ID NO:19, VH CDR3 of SEQ ID NO:20, a VL CDR1 of SEQ ID NO:30, a VL CDR2 of SEQ ID NO:31, and a VL CDR3 of SEQ ID NO:32.

2. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof is a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a synthetic antibody, a single chain antibody, a diabody, a caninized antibody, a canine antibody, a human antibody, or a CDR-grafted antibody.

3. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein (i) the antibody or antigen-binding portion thereof comprising a VH CDR1 of SEQ ID NO:9, a VH CDR2 of SEQ ID NO:10, VH CDR3 of SEQ ID NO:11, comprises a VL amino acid sequence of SEQ ID NO:5;

(ii) the antibody or antigen-binding portion thereof comprising a VH CDR1 of SEQ ID NO:12, a VH CDR2 of SEQ ID NO:13, VH CDR3 of SEQ ID NO:14, comprises a VL amino acid sequence of SEQ ID NO:6;

(iii) the antibody or antigen-binding portion thereof comprising a VH CDR1 of SEQ ID NO:15, a VH CDR2 of SEQ ID NO:16, VH CDR3 of SEQ ID NO:17, comprises a VL amino acid sequence of SEQ ID NO:7;

(iv) the antibody or antigen-binding portion thereof comprising a VH CDR1 of SEQ ID NO:18, a VH CDR2 of SEQ ID NO:19, VH CDR3 of SEQ ID NO:20, comprises a VL amino acid sequence of SEQ ID NO:8.

4. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein said (i) antibody or antigen-binding portion thereof comprising a VL CDR1 of SEQ ID NO:21, a VL CDR2 of SEQ ID NO:22, and a VL CDR3 of SEQ ID NO:23 comprises a VH amino acid sequence of SEQ ID NO:1;

(ii) antibody or antigen-binding portion thereof comprising a VL CDR1 of SEQ ID NO:24, a VL CDR2 of SEQ ID NO:25, and a VL CDR3 of SEQ ID NO:26 comprises a VH amino acid sequence of SEQ ID NO:2;

(iii) antibody or antigen-binding portion thereof comprising a VL CDR1 of SEQ ID NO:27, a VL CDR2 of SEQ ID NO:28, and a VL CDR3 of SEQ ID NO:29 comprises a VH amino acid sequence of SEQ ID NO:3;

(iv) antibody or antigen-binding portion thereof comprising a VL CDR1 of SEQ ID NO:30, a VL CDR2 of SEQ ID NO:31, and a VL CDR3 of SEQ ID NO:32 comprises a VH amino acid sequence of SEQ ID NO:4.

5. A composition comprising the antibody or antigen-binding portion thereof of claim 1 and a pharmaceutically acceptable carrier.

6. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof is an IgG1, an IgG2, an IgG2 a , an IgG2 b , an IgG3, or an IgG4.

7. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof specifically binds canine CD20 with an affinity (K d ) of at least about 10 −6 M.

8. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein said antibody or antigen-binding portion thereof induces apoptosis of CD20+cells.

9. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma ATCC number PTA-9433 (4F1), ATCC number PTA-9434 (6C8), ATCC number PTA -9435 (14A12), or ATCC number PTA-9436 (18D3).

10. The antibody or antigen-binding portion thereof of claim 1 , wherein the antibody is produced by the hybridoma cell line having ATCC number PTA-9433 (4F1), ATCC number PTA-9434 (6C8), ATCC number PTA-9435 (14A12), or ATCC number PTA-9436 (18D3).

11. An isolated cell of hybridoma ATCC number PTA-9433 (4F1), ATCC number PTA-9434 (6C8), ATCC number PTA-9435 (14A12), or ATCC number PTA-9436 (18D3).

12. The isolated antibody or antigen-binding portion thereof of claim 1 , wherein said antibody or antigen-binding portion thereof specifically binds to the surface of canine lymphocytes.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2010
From: BEALL, MELISSA J.
To: IDEXX LABORATORIES, INC.
Reel/Frame 025764/0777 →
Continuity (5)
Continuation In Part 11828464 · Jul 26, 2007
Division 11138949 · May 26, 2005
Provisional Application 61258647 · Nov 6, 2009
Provisional Application 60575172 · May 28, 2004
Related Publication 20110091483A1 · Apr 21, 2011